Galactosin-1 induces EMT in HCC through activating FAK/PI3K/AKT signaling pathway to enhance sorafenib resistance and is a biomarker for predicting sorafenib sensitivity. The gene discussed is AKT1; the disease is hepatocellular carcinoma.